Background and Purpose: Robotic assisted radical prostatectomy (RARP) is a popular treatment option for localized prostate cancer.
Literature is lacking on the effect of advanced age on complication rates in men undergoing robotic prostatectomy. We performed a comparative analysis of complication rates for men ≤ 69 and ≥70 years undergoing RARP.
Methods: After IRB approval, we reviewed our initial 1000 consecutive patients who underwent RARP from 6/2002 to 6/2011 for intraoperative and postoperative complications, and we compared complication rates stratified by age ≤ 69 and ≥70 years. Complications were graded according to the Clavien-Dindo classification system. The Fischer's exact test was used to compare complication rates and a p- value of < 0.05 was considered statistically significant.
Results: In our cohort, 868 men were ≤ 69 and 129 men were ≥70. Overall, the intraoperative and postoperative complication rates for the entire cohort were 0.90% and 10.2%, respectively. There was no statistically significant difference in individual postoperative complications between the two groups, however, the overall postoperative complications rates for men ≤ 69 and ≥70 was 9.4% and 15.4%, respectively (p-value=0.043). Major complication rates for men ≤ 69 and ≥70 were 6.7% (58) and 10.8% (14), respectively (p=0.10); minor complications rates, 2.8% (22) and 4.6% (6), respectively (p=0.25).
Conclusions: In our study, men ≥70 had a significantly higher overall complication rate after RARP compared to men ≤ 69 years; however the individual, minor, and major complications were not different between the two groups. RARP is relatively safe in this older age group. Identifying complications and proposing insightful working solutions has decreased both minor and major complication rates after RARP.
Written by:
Babaian K, Skarecky D, Liss MA, Osann KE, Lusch A, Ahlering T. Are you the author?
University of California Irvine, Urology, 2233 Martin Apt 300, Orange, California, United States.
Reference: J Endourol. 2014 Aug 1. Epub ahead of print.
doi: 10.1089/end.2014-0234.ECC14
PubMed Abstract
PMID: 25083797
UroToday.com Prostate Cancer Section
